5 Stocks Winning by Double Digits

In this article, we deep dive into the 5 stocks that defied the lackluster performance of the broader market. For a deeper discussion and an extended list, please see 9 Stocks Winning by Double Digits.

Photo by Mizuno K on Pexels

5. Nurix Therapeutics Inc. (NASDAQ:NRIX)

Nurix Therapeutics extended its gains to an 8th straight session on Thursday, touching a new 52-week high, as investors resumed buying positions following an earlier partnership with Roche for the co-development of a blood cancer treatment.

In intra-day trading, the stock climbed to a record high of $23.09 before trimming gains to end the day just up by 16.37 percent at $22.46 apiece.

In a statement, Nurix Therapeutics Inc. (NASDAQ:NRIX) said that it joined forces with Roche to develop and commercialize bexobrutideg, a potential best-in-class oral degrader of Bruton’s tyrosine kinase (BTK).

According to the two parties, the collaboration encompasses a comprehensive clinical development plan spanning malignant hematology, immunology and neurology intended to explore the full clinical potential of BTK degradation across diverse patient populations. In addition to the Phase 2 and Phase 3 trials in chronic lymphocytic leukemia, the collaboration plans to pursue multiple label-enabling studies across a range of malignant hematology indications as monotherapy and in combination regimens,  and expand development into immune-mediated diseases, including Phase 2 trials in MS and CSU.

“Partnering with Roche, a world leader in the treatment of B-cell malignancies, positions Nurix to fully realize the potential of bexobrutideg across multiple indications in oncology, immunology, and neurology,” Nurix Therapeutics Inc. (NASDAQ:NRIX) President and CEO Arthur Sands said.

As part of the agreement, Nurix Therapeutics Inc. (NASDAQ:NRIX) is set to receive $700 million in upfront cash payments and is eligible to receive up to $2.3 billion upon milestone achievement.